Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2011-04-22 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
北京市君泽君律师事务所关于公司股票期权激励计划调整事项的法律意见
Regulatory Filings Classification · 95% confidence The document is a legal opinion issued by a law firm regarding adjustments to a stock option incentive plan of Beijing Shuanglu Pharmaceutical Co., Ltd. It discusses the legal basis, adjustment reasons, methods, and approvals related to stock option quantity and exercise price adjustments. The document is a standalone legal opinion on a specific corporate action related to stock options, not a general financial report, earnings release, or management discussion. It does not contain financial statements or quarterly/yearly financial results. It is not an announcement of a report but a legal opinion document. Therefore, it fits best under Regulatory Filings (RNS) as it is a legal compliance document related to corporate governance and stock option adjustments, without being a full governance report or management announcement of board changes.
2011-04-22 Chinese
2010年度权益分派实施公告
Notice of Dividend Amount Classification · 95% confidence The document is titled as an "权益分派实施公告" which translates to "Implementation Announcement of Equity Distribution" for the fiscal year 2010. It details the dividend distribution plan, including stock dividends, cash dividends, and capital reserve transfers, along with relevant dates such as the record date and ex-dividend date. The document also includes shareholder information and shareholding changes due to the distribution. The length is about 2093 characters, which is relatively short and the content is focused on announcing the dividend distribution details rather than presenting a full financial report or earnings release. This matches the definition of a Notice of Dividend Amount (DIV), which announces dividend amounts, payment dates, and details for shareholders. Therefore, the correct classification is DIV with high confidence.
2011-04-21 Chinese
2011年第一季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2011 First Quarter Quarterly Report" of Beijing Shuanglu Pharmaceutical Co., Ltd. It contains detailed financial data for the first quarter of 2011, including total assets, equity, revenue, net profit, cash flow, earnings per share, and other financial indicators. It also includes management's explanations for significant changes in financial items, shareholder information, and forecasts for the next half-year period. The presence of comprehensive financial statements and substantive financial analysis for a period shorter than a full fiscal year clearly identifies this as an Interim / Quarterly Report. The document length is about 4861 characters, which is sufficient to contain actual financial data and analysis, not just an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q1 2011
2011-04-15 Chinese
2011年第一季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2011 First Quarter Quarterly Report" of Beijing Shuanglu Pharmaceutical Co., Ltd. It contains detailed financial data including balance sheets, income statements, cash flow statements, and management commentary on financial performance for the first quarter of 2011. The report explicitly states it is a quarterly report and includes comprehensive financial figures and analysis for the quarter. The document length is over 12,000 characters, indicating it is a full report rather than a brief announcement. There is also a note that the financial report is unaudited, which is typical for quarterly reports. Based on these characteristics, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2011
2011-04-15 Chinese
第四届董事会第十七次临时会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement of a board resolution from Beijing Shuanglu Pharmaceutical Co., Ltd. regarding the acquisition of a 12% equity stake in another company. It details the board meeting date, voting results, and transaction specifics. There is no financial report, audit, or earnings data presented. The document is not a full report but an announcement of a board decision related to a capital transaction. It fits best under Capital/Financing Update (CAP) as it concerns a financing activity (equity acquisition) approved by the board.
2011-04-01 Chinese
关于收购北京普仁鸿医药销售有限公司部分股权的关联交易公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Beijing Shuanglu Pharmaceutical Co., Ltd. regarding the acquisition of a 12% equity stake in Beijing Purenhong Pharmaceutical Sales Co., Ltd. It details the transaction overview, parties involved, financial data of the target company, contract terms, and regulatory compliance. The content focuses on a capital acquisition transaction, including shareholding changes and related party disclosures. There is no indication that this is a full annual or interim report, audit report, or earnings release. It is not a call transcript, AGM material, or voting result announcement. The document is a detailed announcement of a capital/financing update related to a share acquisition. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2011-04-01 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.